Is Checkpoint Therapeutics, Inc. overvalued or undervalued?

As of 6 May 2021, the valuation grade for Checkpoint Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its high Price to Book Value of 22.75, an EV to Sales ratio of 337.66, and a negative ROE of -345.95%. In comparison, Journey Medical Corp. has a P/E of -18.6994 and Fortress Biotech, Inc. has a P/E of -1.1589, both indicating that Checkpoint is not competitively positioned within its peer group.
Despite the overvaluation, Checkpoint Therapeutics has shown strong short-term performance, with a year-to-date return of 33.12%, significantly outperforming the S&P 500's 12.22%. However, the long-term outlook remains concerning, as the company has experienced a staggering -79.91% return over the past five years compared to the S&P 500's 96.61%.